EDAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edap Tms SA (EDAP) is not a strong buy candidate for a beginner investor with a long-term strategy at this time. The technical indicators are neutral, the options data suggests limited bullish sentiment, and the financial performance shows declining profitability. While there are some positive catalysts, such as hedge fund interest and the company's leadership in its niche market, these are outweighed by negative financial trends and lack of strong trading signals.
The MACD histogram is negative and contracting, indicating a bearish trend. RSI is neutral at 43.255, and moving averages are converging, suggesting no clear directional trend. The stock is trading near its pivot level of 4.314, with key resistance at 4.791 and support at 3.837.
Hedge funds have significantly increased their buying activity by 13044.55% over the last quarter. The company continues to lead in robotic energy-based therapies and minimally invasive medical devices, with its Focal One® device gaining traction in Europe and the U.S.
Insiders are neutral, showing no significant trading activity. The financial performance in Q3 2025 shows declining net income (-21.64% YoY) and EPS (-23.53% YoY), which could deter long-term investors. Additionally, the stock has an 80% chance of declining -4.13% over the next month based on historical candlestick patterns.
In Q3 2025, revenue increased by 5.96% YoY to $13,879,000, and gross margin improved by 9.33% to 43.02%. However, net income dropped by 21.64% YoY to -$5,014,000, and EPS fell by 23.53% to -0.13, reflecting declining profitability.
No recent analyst rating or price target changes were provided.
